ALEXANDRIA, Va., Oct. 15, 2013 /PRNewswire/ -- The Liver Meeting® is the premier Annual Meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies.
Approximately 10 percent of Americans have some form of liver disease, but fortunately, the research community has made great strides in recent years in developing new treatments for patients.
At this year's meeting, 2306 abstracts addressing these issues that will be presented, including 270 abstracts that will be presented in oral sessions. Those abstracts are available to members of the press at our website (www.aasld.org).
Washington, DC: November 1 – 5, 2013
- Poster Presentations: November 2 – 5
- Oral Presentations: November 3 – 5
An AASLD President's press conference highlighting key abstracts and issues presented at The Liver Meeting® is scheduled for Saturday, November 2 at 4:00 pm.
The following two programs will highlight the latest in viral hepatitis treatment:
- The HCV Symposium will discuss the integration of new therapies for the treatment of chronic hepatitis
- The Hepatitis Debrief will provide a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®
Founded in 1950, AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD has grown into an international society responsible for all aspects of hepatology, and our annual meeting attracts more than 9,500 physicians, surgeons, researchers, and allied health professionals from around the world.
Please contact AASLD at 703-299-9766 for information about the above presentations, or to receive any additional information about The Liver Meeting® – or visit our website at www.aasld.org.
This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.
SOURCE American Association for the Study of Liver Diseases (AASLD)